Skip to content

Cytosorbents Corp

CTSO· NasdaqCore metricsCIK 1175151

Surgical & medical instruments & apparatus143 peers

Last sale
Nov 11, 2026 · -7.03%
Market cap
$349.09M
62.84M shares
Filings
979
$9.63M
Q2 2026+4.1% FY25 yoy
-$4.42M
Q2 2026N/M FY25 yoy
-$2.64M
Q2 2026N/M FY25 yoy
-$1.77M
Q2 2026derivedN/M FY25 yoy
-$0.07
Q2 2026N/M FY25 yoy
$4.41M
Q2 2026+90.5% FY25 yoy
$349.09M
—
9.4×
—
-2.66%
—

Twelve months to Jun 30, 2026 · derived

Price

$5.56+678.99%+$4.84past year
Nov 11, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$37.06MFY 2025
$43.17M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$37,063,000reported
FY 20242024-12-31$35,595,000reported
FY 20232023-12-31$31,084,953 revisedreported
FY 20222022-12-31$34,688,809reported
FY 20212021-12-31$43,165,527reported
FY 20202020-12-31$41,004,601reported
FY 20192019-12-31$24,949,473reported
FY 20182018-12-31$22,503,908reported
FY 20172017-12-31$15,150,754reported
FY 20162016-12-31$9,527,843reported
FY 20152015-12-31$4,791,616reported
FY 20142014-12-31$4,122,825reported

Segments

Products
Revenue by Products, FY2018 to FY2023FY2018Total product sales · FY2018 · $20.25MCytoSorb sales · FY2018 · $20.14MGrant income · FY2018 · $2.25MOther product sales · FY2018 · $109.03KFY2019Total product sales · FY2019 · $22.77MCytoSorb sales · FY2019 · $22.55MGrant income · FY2019 · $2.18MOther product sales · FY2019 · $220.10KFY2020Total product sales · FY2020 · $39.45MCytoSorb sales · FY2020 · $39.34MGrant income · FY2020 · $1.55MOther product sales · FY2020 · $110.40KFY2021Total product sales · FY2021 · $40.11MCytoSorb sales · FY2021 · $40.00MGrant income · FY2021 · $3.06MOther product sales · FY2021 · $111.87KFY2022Total product sales · FY2022 · $29.36MCytoSorb sales · FY2022 · $28.57MGrant income · FY2022 · $5.33MOther product sales · FY2022 · $787.20KFY2023Total product sales · FY2023 · $31.08MCytoSorb sales · FY2023 · $31.02MGrant income · FY2023 · $5.26MOther product sales · FY2023 · $69.69K
LineFY2023ShareChange
Total product sales$31.08M100%+5.9%
CytoSorb sales$31.02M100%+8.5%
Grant income$5.26M17%−1.2%
Other product sales$69.69K0.2%−91.1%
Total$31.08M

From the 10-K filed Mar 15, 2024CTSO

Surgical & medical instruments & apparatus

Cytosorbents Corp is the 72nd largest of the 144 covered companies the SEC files under this code, by revenue. SIC 3841

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Cytosorbents Corp · CIK 1175151 · Engraved from SEC EDGAR